Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s stock price hit a new 52-week low on Tuesday . The company traded as low as $20.25 and last traded at $20.09, with a volume of 133465 shares changing hands. The stock had previously closed at $21.26.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. The Goldman Sachs Group raised shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Wedbush reiterated an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Finally, Robert W. Baird boosted their price objective on Spyre Therapeutics from $50.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $54.83.
View Our Latest Analysis on SYRE
Spyre Therapeutics Stock Up 7.2 %
The firm's 50 day simple moving average is $22.45 and its 200 day simple moving average is $26.83. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -2.64 and a beta of 2.85.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.08. Analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Institutional Investors Weigh In On Spyre Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of SYRE. Emerald Mutual Fund Advisers Trust acquired a new position in Spyre Therapeutics during the 3rd quarter valued at about $7,457,000. Emerald Advisers LLC bought a new position in shares of Spyre Therapeutics in the third quarter valued at approximately $8,604,000. Quest Partners LLC increased its stake in shares of Spyre Therapeutics by 271.2% during the third quarter. Quest Partners LLC now owns 5,654 shares of the company's stock valued at $166,000 after acquiring an additional 4,131 shares during the period. Intech Investment Management LLC bought a new stake in Spyre Therapeutics during the third quarter worth approximately $246,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Spyre Therapeutics by 239.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company's stock worth $9,802,000 after purchasing an additional 235,094 shares during the period. 80.39% of the stock is currently owned by institutional investors.
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Articles
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
